Literature DB >> 19546526

Ischemic preconditioning attenuates renal ischemia-reperfusion injury by inhibiting activation of IKKbeta and inflammatory response.

Xin Chen1, Xiaodong Liu, Xin Wan, Yu Wu, Yu Chen, Changchun Cao.   

Abstract

BACKGROUND: Renal ischemia-reperfusion (I/R) injury is a major cause of acute renal failure (ARF). The transcription factor nuclear factor-kappaB (NF-kappaB) has been implicated as a key mediator of reperfusion injury. Activation of NF-kappaB is dependent upon the phosphorylation of its inhibitor, IkappaB, by the specific inhibitory kappaB kinase (IKK) subunit, IKKbeta. We hypothesized that ischemic preconditioning (IPC) reduces acute renal damage following I/R injury by inhibiting activation of IKKbeta. As neutrophil gelatinase-associated lipocalin (NGAL), an early predictive biomarker of acute kidney injury, is regulated by NF-kappaB, we approached the relationship between NGAL and IKKbeta.
METHOD: Thirty male Sprague-Dawley rats were randomly divided into 3 groups after right kidney nephrectomy. Group A rats were sham-operated controls. Group B rats were 45-min ischemic in the left renal artery while Group C rats were pre-treated with 3 cycles of 2-min ischemia and 5-min reperfusion. All the rats were sacrificed at 24 h after reperfusion. We harvested kidneys and serum to do further analysis, including histological and functional parameters, expressions of NGAL and IKKbeta in renal tissues.
RESULTS: Compared with rats subjected to I/R injury, pre-treated rats had a significant decrease in serum creatinine level (Scr) and tubulointerstitial injury scores (Scr, 86.79 +/- 12.98 vs. 205.89 +/- 19.16 mircomol/l, p < 0.01; tubulointerstitial injury scores, 1.3 +/- 0.48 vs. 3.8 +/- 0.79, p < 0.01). In addition, expressions of IKKbeta (0.95 +/- 0.21 vs. 1.74 +/- 0.17, p < 0.05) and NGAL (1.71 +/- 0.032 vs. 2.66 +/- 0.078, p < 0.05) at renal tubule in pre-treated rats were attenuated significantly compared with rats subjected to ischemia-reperfusion injury. Moreover, our study showed that IKKbeta and NGAL were in positive correlation (R = 0.965 > R(0.01)(30) = 0.448, p < 0.01).
CONCLUSIONS: The evidence suggests that IKKbeta may play a role in renal I/R injury and give rise to the generation of NGAL. It appears that IPC may attenuate renal injury and the expression of NGAL following acute I/R injury. IKKbeta may offer a clinically accessible target for preventing renal injury following I/R. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546526     DOI: 10.1159/000225928

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  20 in total

1.  Renal hypoperfusion and impaired endothelium-dependent vasodilation in an animal model of VILI: the role of the peroxynitrite-PARP pathway.

Authors:  Rosanna Vaschetto; Jan W Kuiper; René J P Musters; Etto C Eringa; Francesco Della Corte; Kanneganti Murthy; A B Johan Groeneveld; Frans B Plötz
Journal:  Crit Care       Date:  2010-03-26       Impact factor: 9.097

Review 2.  From rapid to delayed and remote postconditioning: the evolving concept of ischemic postconditioning in brain ischemia.

Authors:  Heng Zhao; Chuancheng Ren; Xingmiao Chen; Jiangang Shen
Journal:  Curr Drug Targets       Date:  2012-02       Impact factor: 3.465

3.  Repetitive ischemic preconditioning attenuates inflammatory reaction and brain damage after focal cerebral ischemia in rats: involvement of PI3K/Akt and ERK1/2 signaling pathway.

Authors:  Xian-kun Tu; Wei-zhong Yang; Jian-ping Chen; Yan Chen; Quan Chen; Ping-ping Chen; Song-sheng Shi
Journal:  J Mol Neurosci       Date:  2014-10-22       Impact factor: 3.444

Review 4.  Ischaemic preconditioning for the reduction of renal ischaemia reperfusion injury.

Authors:  Theo P Menting; Kimberley E Wever; Denise Md Ozdemir-van Brunschot; Daan Ja Van der Vliet; Maroeska M Rovers; Michiel C Warle
Journal:  Cochrane Database Syst Rev       Date:  2017-03-04

5.  Sinomenine protects mice against ischemia reperfusion induced renal injury by attenuating inflammatory response and tubular cell apoptosis.

Authors:  Zhiqing Zhao; Rui Guan; Shaohua Song; Mingjian Zhang; Fang Liu; Meng Guo; Wenyuan Guo; Qilin Yu; Luding Zhang; Quanxing Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

6.  Using hormetic strategies to improve ischemic preconditioning and postconditioning against stroke.

Authors:  Heng Zhao; Sungpil Joo; Weiying Xie; Xunming Ji
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2013-05-27

Review 7.  Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis.

Authors:  Kimberley E Wever; Theo P Menting; Maroeska Rovers; J Adam van der Vliet; Gerard A Rongen; Rosalinde Masereeuw; Merel Ritskes-Hoitinga; Carlijn R Hooijmans; Michiel Warlé
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

8.  Lipopolysaccharide Pretreatment Prevents Medullary Vascular Congestion following Renal Ischemia by Limiting Early Reperfusion of the Medullary Circulation.

Authors:  Sarah R McLarnon; Katie Wilson; Bansari Patel; Jingping Sun; Christina L Sartain; Christopher D Mejias; Jacqueline B Musall; Jennifer C Sullivan; Qingqing Wei; Jian-Kang Chen; Kelly A Hyndman; Brendan Marshall; Haichun Yang; Agnes B Fogo; Paul M O'Connor
Journal:  J Am Soc Nephrol       Date:  2022-02-03       Impact factor: 14.978

9.  Test clamp procedure in robot-assisted partial nephrectomy: is it a safe procedure?

Authors:  Takahiro Nohara; Suguru Kadomoto; Hiroaki Iwamoto; Hiroshi Yaegashi; Masashi Iijima; Shohei Kawaguchi; Takashi Shima; Kazuyoshi Shigehara; Kouji Izumi; Yoshifumi Kadono; Chikashi Seto; Atsushi Mizokami
Journal:  J Robot Surg       Date:  2021-07-27

10.  Ischemic preconditioning increases endothelial progenitor cell number to attenuate partial nephrectomy-induced ischemia/reperfusion injury.

Authors:  Hao Liu; Ran Wu; Rui-Peng Jia; Bing Zhong; Jia-Geng Zhu; Peng Yu; Yan Zhao; Yu-Zheng Ge; Jian-Ping Wu
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.